Adrian Newman-Tancredi
is co-founder and
Chief Scientific Officer
Neurolixis Inc.



Adrian Newman-Tancredi, PhD, DSc, gave an invited lecture on Monday 19 January 2015 at the highly-recognized School of Physiology and Pharmacology of Bristol University (UK). The...Read More
Neurolixis, a bioscience company co-founded by Adrian Newman-Tancredi, has announced a drug discovery collaboration with Jagiellonian University in Krakow, Poland. The collaboration...Read More
Adrian Newman-Tancredi will be chairing a session at the World Orphan Drug Congress in Brussels, Belgium, on 12th to 14th October 2014. Dr. Newman-Tancredi has been invited to chair...Read More

NeuroAct Communication offers independent consulting in neuropharmacology and preclinical drug discovery to
bioscience companies, agencies and the investment community.